In breast cancer treatment, the CDK4/6 inhibitor Palbociclib is often combined with Letrozole, an inhibitor of aromatase in estrogen production, but this only makes sense when treating estrogen-dependent tumors1. Here, CDK4 is linked to substance dependence.